Fortress Biotech Inc Dossier - Source-backed chat

Fortress Biotech Inc

FBIONASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.11

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.07Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $69M

Enterprise Value −$92.5M

Shares Outstanding 35.7M diluted

Moat Rating None

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Fortress Biotech, Inc. (NASDAQ: FBIO) represents a compelling buy opportunity following a pivotal transition to profitability in early 2026. The company's unique business model—focused on acquiring, developing, and monetizing clinical-stage biopharmaceutical assets through partner companies—has been validated by three FDA approvals in the last 15 months (Emrosi, UNLOXCYT, and ZYCUBO). The landmark $205 million sale of Cyprium's Rare Pediatric Disease Priority Review Voucher (PRV) in March 2026 has dramatically strengthened Fortress's balance sheet, boosting consolidated cash to $255.8 million and allowing the company to pay down its Oaktree debt principal to just $15.0 million. With a robust commercial dermatology engine via Journey Medical (which grew Q1 2026 revenue by 21% YoY to $16.0 million) and high-optionality royalty streams from UNLOXCYT and ZYCUBO, Fortress is well-positioned to generate long-term shareholder value with significantly reduced financial risk.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$11.00

High · most bullish analyst$17.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects potential commercial headwinds for Emrosi due to intense competition in the rosacea market or unfavorable payer coverage dynamics. Furthermore, slower-than-expected royalty ramps for UNLOXCYT and ZYCUBO, combined with clinical setbacks or regulatory delays in early-stage pipeline programs at Mustang Bio or Avenue Therapeutics, could pressure the valuation.

Base CaseCentral scenario

The base case assumes continued commercial momentum for Emrosi in the dermatology segment, driving Journey Medical toward sustained positive Adjusted EBITDA. Royalties from Sun Pharma's launch of UNLOXCYT and Sentynl's commercialization of ZYCUBO begin to contribute high-margin cash flows. The company maintains a disciplined cash burn rate and leverages its strengthened balance sheet to advance early-stage pipeline candidates without immediate dilutive equity raises.

Bull CaseUpside scenario

Successful commercial scaling of Emrosi by Journey Medical combined with milestone monetization from partnered assets like ZYCUBO and UNLOXCYT, driving Fortress to sustained profitability.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proven business model with three FDA approvals achieved within a 15-month window (Emrosi, UNLOXCYT, ZYCUBO).
Dramatically improved balance sheet with $255.8 million in consolidated cash and Oaktree debt principal reduced to $15.0 million following the $205 million PRV sale.
Strong commercial engine in Journey Medical, which delivered 21% YoY revenue growth in Q1 2026, driven by Emrosi.
High-margin royalty optionality from partner-led commercializations (2.5% on UNLOXCYT net sales by Sun Pharma and tiered royalties on ZYCUBO by Sentynl).

Key Investment Risks

Heavy reliance on partner execution (Sun Pharma, Sentynl, AstraZeneca) for royalty generation and milestone achievements.
Commercial execution risks in the highly competitive dermatology market, particularly regarding payer coverage and reimbursement rates for Emrosi.
Inherent clinical and regulatory risks associated with early-stage pipeline candidates developed by majority-owned subsidiaries (Mustang Bio, Avenue Therapeutics).

Thesis Invalidation Triggers

A significant slowdown in Emrosi prescription growth or a major contraction in gross-to-net margins at Journey Medical.
Failure of partners to successfully commercialize UNLOXCYT or ZYCUBO, resulting in negligible royalty streams.
Unexpected regulatory setbacks or clinical trial failures for late-stage pipeline assets such as anselamimab (CAEL-101).

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.